Business
Savara Announces Amendment to Hercules Capital Debt Facility Providing up to $75M of Additional Debt Funding Upon U.S. Food and Drug Administration (FDA) Approval of MOLBREEVI*
LANGHORNE, Pa., January 27, 2026--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the amendment of its loan and security agreement with Hercules Capital, Inc. (NYSE:HTGC), strengthening its balance sheet and liquidity.
About this update from Hercules Capital, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/5c0d5680f74206b0d603b34656ffa825"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ygE0IW42Q1oldIwqInubdw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/5c0d5680f74206b0d603b34656ffa825","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/cCO0cbBDgfm2tcFUAK62bw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/5c0d5680f74206b0d603b34656ffa825","width":1024,"height":512}},"lazy":false},{"type":"text","content":"-- When Combined with Recently Announced $75M Royalty Financing, the Company Will Have Access to ~$150M of Non-Dilutive Capital for Launch of MOLBREEVI --","length":154,"tagName":"p","attribs":{}},{"type":"text","content":"LANGHORNE, Pa., January 27, 2026--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the amendment of its loan and security agreement with Hercules Capital, Inc. (NYSE:HTGC), strengthening its balance sheet and liquidity.","length":326,"tagName":"p"},{"type":"text","content":"Under the terms of the amended loan agreement, up to an additional $75 million will become available upon FDA’s approval of MOLBREEVI, the Company’s investigational therapy in autoimmune pulmonary alveolar proteinosis (autoimmune PAP). The loan agreement maturity date and interest-only period remain unchanged. There are no warrants in connection with the agreement.","length":367,"tagName":"p"},{"type":"text","content":""In anticipation of the potential approval of MOLBREEVI later this year, Savara will be well capitalized with ~$150 million of non-dilutive capital to support launch activities," said Dave Lowrance, Chief Financial and Administrative Officer, Savara. "This includes the amended debt facility announced today combined with the strategic royalty financing from RTW announced in October last year."","length":415,"tagName":"p"},{"type":"text","content":""Hercules Capital is thrilled to continue our partnership with Savara as they prepare for the potential launch of MOLBREEV...